 Norwood, MA, April 20, 2021 GLOBE NEWSWIRE -- Corbus Pharmaceuticals Holdings, Inc. NASDAQ: CRBP Corbus or the Company, a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that the last participant was enrolled in a Phase 2 study of lenabasum for the treatment of systemic lupus erythematosus SLE. 